Brief: Silo Pharma Announces Positive Results From Study For Depression Treatment, Remission, And Relapse Prevention
21/05/2024 14:06
May 21 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ANNOUNCES POSITIVE RESULTS FROM STUDY FOR
DEPRESSION
TREATMENT, REMISSION, AND RELAPSE PREVENTION
* SILO PHARMA INC - EXPECTS TO COMPLETE AND ENTER INTO
EXCLUSIVE
LICENSE AGREEMENT IN FIRST HALF OF 2024
* SILO PHARMA - UNDER TERMS OF LICENSE AGREEMENT, TO BE
GRANTED
EXCLUSIVE LICENSE TO FURTHER DEVELOP, MANUFACTURE, AND
COMMERCIALIZE SPC-15 WORLDWIDE
Source text for Eikon: ID:nGNXc8tRq9
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement